{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"BAX","limit":50},"count":50,"signals":[{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":45,"context":"on consultant, the CHC Committee reviewed Baxters material compensation policies and practices and concluded that these policies and practices do not create risks that are reasonably likely to have a material adverse effect on the company. The key features of the executive compensation program as well as incentive and commission arrangements below the executive level that support this conclusion include:  appropriate pa","filed_date":"2026-03-23","accession":"0001628280-26-020330","full_text":"https://origin.rootz.global/static/filing/0001628280-26-020330.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":33,"context":"mittees of the Board | 32 | | | Director Compensation | 36 | | | Sustainability and Corporate Responsibility | 39 | | | | Executive Compensation | 41 | | | | | | Proposal 2 - Advisory Vote to Approve Named Executive Officer Compensation for 2025 | 41 | | | | | | Compensation and Human Capital Committee Report | 42 | | | Compensation Discussion and Analysis | 43 | | | Executive Summary | 44 | | | Structure of Executive C","filed_date":"2026-03-23","accession":"0001628280-26-020330","full_text":"https://origin.rootz.global/static/filing/0001628280-26-020330.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":23,"context":"e successful in achieving expected operating efficiencies and sustaining or improving operating expense reductions and may experience business disruptions and adverse tax consequences associated with restructuring initiatives.  Portions of our business have been, and will be, the subject of various restructuring initiatives. For example, we recently divested our BPS and Kidney Care businesses. In addition, we are working","filed_date":"2026-02-12","accession":"0001628280-26-007733","full_text":"https://origin.rootz.global/static/filing/0001628280-26-007733.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":110,"context":"our business, results of operations, financial condition, cash flows, future growth prospects, reputation or stock price could suffer. Further, other unknown or unpredictable factors could also have significant adverse effects on our future results.  Risk Factors Summary This summary of risks below is intended to provide an overview of the risks we face and should not be considered a substitute for the more detailed risk","filed_date":"2026-02-12","accession":"0001628280-26-007733","full_text":"https://origin.rootz.global/static/filing/0001628280-26-007733.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":19,"context":"mitigate a portion of the dis-synergies that arose as a result of the sale of our Kidney Care business, and to the extent further cost savings opportunities are identified, we would incur additional restructuring charges and costs to implement business optimization programs in future periods. For segment reporting, business optimization charges are unallocated expenses.20During the three and nine months ended Septemb","filed_date":"2025-11-04","accession":"0001628280-25-048897","full_text":"https://origin.rootz.global/static/filing/0001628280-25-048897.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":10,"context":"esolution thereof in any reporting period could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur","filed_date":"2025-11-04","accession":"0001628280-25-048897","full_text":"https://origin.rootz.global/static/filing/0001628280-25-048897.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":14,"context":"mitigate a portion of the dis-synergies that arose as a result of the sale of our Kidney Care business, and to the extent further cost savings opportunities are identified, we would incur additional restructuring charges and costs to implement business optimization programs in future periods. For segment reporting, business optimization charges are unallocated expenses.During the three and six months ended June30, 20","filed_date":"2025-08-05","accession":"0001628280-25-037877","full_text":"https://origin.rootz.global/static/filing/0001628280-25-037877.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":10,"context":"esolution thereof in any reporting period could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur","filed_date":"2025-08-05","accession":"0001628280-25-037877","full_text":"https://origin.rootz.global/static/filing/0001628280-25-037877.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":12,"context":"mitigate a portion of the dis-synergies that arose as a result of the sale of our Kidney Care business, and to the extent further cost savings opportunities are identified, we would incur additional restructuring charges and costs to implement business optimization programs in future periods. For segment reporting, business optimization charges are unallocated expenses.During the three months ended March31, 2025 and","filed_date":"2025-05-06","accession":"0001628280-25-022727","full_text":"https://origin.rootz.global/static/filing/0001628280-25-022727.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":10,"context":"esolution thereof in any reporting period could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur","filed_date":"2025-05-06","accession":"0001628280-25-022727","full_text":"https://origin.rootz.global/static/filing/0001628280-25-022727.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":42,"context":"on consultant, the CHC Committee reviewed Baxters material compensation policies and practices and concluded that these policies and practices do not create risks that are reasonably likely to have a material adverse effect on the company. The key features of the executive compensation program as well as incentive and commission arrangements below the executive level that support this conclusion include: appropriate pay","filed_date":"2025-03-25","accession":"0001628280-25-014747","full_text":"https://origin.rootz.global/static/filing/0001628280-25-014747.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":41,"context":"| Board Structure and Processes | 25 | | | | | Committees of the Board | 27 | | | | | Director Compensation | 31 | | | | | Corporate Responsibility | 34 | | | | | Proposal 2 Advisory Vote to Approve Named Executive Officer Compensation for 2024 | 37 | | | | | Compensation and Human Capital Committee Report | 38 | | | | | Compensation Discussion and Analysis | 38 | | | | | Executive Summary | 39 | | | | | Structure of E","filed_date":"2025-03-25","accession":"0001628280-25-014747","full_text":"https://origin.rootz.global/static/filing/0001628280-25-014747.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":20,"context":"lizing and streamlining certain support functions. The costs of restructuring actions consisted primarily of employee termination costs, contract termination costs and asset impairments.  We incurred restructuring charges of $162 million, $174 million and $193 million in 2024, 2023 and 2022, respectively. In 2024, $45 million of the restructuring charges, consisting of employee termination costs, were related to initi","filed_date":"2025-02-21","accession":"0001628280-25-007201","full_text":"https://origin.rootz.global/static/filing/0001628280-25-007201.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":128,"context":"low occurs, our business, results of operations, financial condition, cash flows, future growth prospects and stock price could suffer. Further, other unknown or unpredictable factors could also have material adverse effects on our future results.  Risk Factors Summary This summary of risks below is intended to provide an overview of the risks we face and should not be considered a substitute for the more detailed risk","filed_date":"2025-02-21","accession":"0001628280-25-007201","full_text":"https://origin.rootz.global/static/filing/0001628280-25-007201.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":16,"context":"to simplify and streamline our operations, and to the extent further cost savings opportunities are identified (including after completion of the pending Kidney Care sale), we would incur additional restructuring charges and costs to implement business optimization programs in future periods.During the three and nine months ended September30, 2024 and 2023, we recorded the following charges related to business optimi","filed_date":"2024-11-12","accession":"0001628280-24-047221","full_text":"https://origin.rootz.global/static/filing/0001628280-24-047221.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":10,"context":"esolution thereof in any reporting period could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur","filed_date":"2024-11-12","accession":"0001628280-24-047221","full_text":"https://origin.rootz.global/static/filing/0001628280-24-047221.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":19,"context":"plify and streamline our operations, and to the extent further cost savings opportunities are identified (including after completion of the proposed Kidney Care separation), we would incur additional restructuring charges and costs to implement business optimization programs in future periods.During the three and six months ended June30, 2024 and 2023, we recorded the following charges related to business optimization","filed_date":"2024-08-06","accession":"0001628280-24-034965","full_text":"https://origin.rootz.global/static/filing/0001628280-24-034965.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":10,"context":"esolution thereof in any reporting period could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur","filed_date":"2024-08-06","accession":"0001628280-24-034965","full_text":"https://origin.rootz.global/static/filing/0001628280-24-034965.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":24,"context":"scussions with select private equity investors to explore a potential sale of our Kidney Care business in lieu of the proposed spinoff. Regardless of the separation structure ultimately selected, the separation of our Kidney Care business is currently expected to be completed in late 2024 or early 2025, subject to the satisfaction of customary conditions.Risks and Uncertainties Supply Constraints and Global Ec","filed_date":"2024-08-06","accession":"0001628280-24-034965","full_text":"https://origin.rootz.global/static/filing/0001628280-24-034965.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":15,"context":"se related to our newly implemented operating model, intended to simplify and streamline our operations, and to the extent further cost savings opportunities are identified, we would incur additional restructuring charges and costs to implement business optimization programs in future periods.During the three months ended March31, 2024 and 2023, we recorded the following charges related to business optimization progra","filed_date":"2024-05-02","accession":"0001628280-24-019786","full_text":"https://origin.rootz.global/static/filing/0001628280-24-019786.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":10,"context":"esolution thereof in any reporting period could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur","filed_date":"2024-05-02","accession":"0001628280-24-019786","full_text":"https://origin.rootz.global/static/filing/0001628280-24-019786.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":15,"context":"scussions with select private equity investors to explore a potential sale of our Kidney Care business in lieu of the proposed spinoff. Regardless of the separation structure ultimately selected, the separation of our Kidney Care business is currently expected to be completed during the second half of 2024, subject to the satisfaction of customary conditions.Risks and Uncertainties Supply Constraints and Globa","filed_date":"2024-05-02","accession":"0001628280-24-019786","full_text":"https://origin.rootz.global/static/filing/0001628280-24-019786.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":28,"context":"on consultant, the CHC Committee reviewed Baxters material compensation policies and practices and concluded that these policies and practices do not create risks that are reasonably likely to have a material adverse effect on the company. The key features of the executive compensation program as well as incentive and commission arrangements below the executive level that support this conclusion include:  |  |  |  |  ap","filed_date":"2024-03-25","accession":"0001193125-24-075975","full_text":"https://origin.rootz.global/static/filing/0001193125-24-075975.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":65,"context":"sible without a strong leadership team. We continued to bolster our senior management ranks in 2023 with key additions across our business segments and corporate functions. In October, Joel Grade was appointed Executive Vice President and Chief Financial Officer following an impressive and wide-ranging 25-year tenure with global foodservice leader, Sysco. In Joels first few months at Baxter, the company has already benefited from his deep o","filed_date":"2024-03-25","accession":"0001193125-24-075975","full_text":"https://origin.rootz.global/static/filing/0001193125-24-075975.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":25,"context":"eamlining certain support functions. The costs of these actions consisted primarily of employee termination costs, implementation costs, contract termination costs and asset impairments.  We incurred restructuring charges of $534 million, $225 million and $114 million in 2023, 2022 and 2021, respectively. In 2023, $111 million of our restructuring charges, consisting of employee termination costs, were related to the","filed_date":"2024-02-08","accession":"0001628280-24-003932","full_text":"https://origin.rootz.global/static/filing/0001628280-24-003932.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":100,"match_count":1,"context":", necessitating significant multi-year capital expenditures in order to meet that demand. However, the impact of such changes and related expenses are difficult to estimate in advance. In addition, a substantial portion of our revenues is dependent on federal healthcare program reimbursement, and any disruptions in federal government operations, including a federal government shutdown or failure of the U.S. government to enact ann","filed_date":"2024-02-08","accession":"0001628280-24-003932","full_text":"https://origin.rootz.global/static/filing/0001628280-24-003932.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":113,"context":"low occurs, our business, results of operations, financial condition, cash flows, future growth prospects and stock price could suffer. Further, other unknown or unpredictable factors could also have material adverse effects on our future results.  Risk Factors Summary This summary of risks below is intended to provide an overview of the risks we face and should not be considered a substitute for the more detailed risk","filed_date":"2024-02-08","accession":"0001628280-24-003932","full_text":"https://origin.rootz.global/static/filing/0001628280-24-003932.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":13,"context":"ern Asian Pharmaceutical Council. Christopher A. Toth, age 44, is Executive Vice President and Group President, Kidney Care. Mr. Toth assumed his responsibilities at Baxter in June 2023 and has been selected as the Chief Executive Officer of the independent company to emerge from the proposed separation of our Kidney Care business into an independent company. Before joining Baxter, he served as Chief Executive Officer of Varian, a Sie","filed_date":"2024-02-08","accession":"0001628280-24-003932","full_text":"https://origin.rootz.global/static/filing/0001628280-24-003932.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":20,"context":"elated to our newly implemented operating model, intended to simplify and streamline our operations, and to the extent further cost  21 savings opportunities are identified, we would incur additional restructuring charges and costs to implement business optimization programs in future periods. During the three and nine months ended September30, 2023 and 2022, we recorded the following charges related to business optim","filed_date":"2023-11-02","accession":"0001628280-23-036195","full_text":"https://origin.rootz.global/static/filing/0001628280-23-036195.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":10,"context":"esolution thereof in any reporting period could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur","filed_date":"2023-11-02","accession":"0001628280-23-036195","full_text":"https://origin.rootz.global/static/filing/0001628280-23-036195.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":16,"context":"ion of our previously announced new operating model intended to simplify and streamline our operations, and, to the extent further cost savings opportunities are identified, we would incur additional restructuring charges and costs to implement business optimization programs in future periods. During the three and six months ended June30, 2023 and 2022, we recorded the following charges related to business optimizatio","filed_date":"2023-07-27","accession":"0001628280-23-025825","full_text":"https://origin.rootz.global/static/filing/0001628280-23-025825.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":23,"context":"Base Salary:Target Compensation Summary Compensation Table and Realizable Pay value for Mr.Almeidas salary are identical.  Annual Bonus: Mr.Almeidas 2020 target bonus was $2,145,000. In light of the substantial negative impact of the COVID-19 pandemic on the companys employees, patients, customers, stockholders and other stakeholders generally, Mr.Almeida recommended to the full Board that his 2020 annual incentive payout","filed_date":"2023-03-23","accession":"0001193125-23-077304","full_text":"https://origin.rootz.global/static/filing/0001193125-23-077304.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":38,"context":"of Thermo Fisher Scientific Inc. I also extend my deep appreciation to two board members departing this April following long, valued tenures: Albert Stroucken, who has been with us since 2004 and was appointed Lead Independent Director in February 2021 after having served as the chair of our Audit Committee; and Thomas Chen, who has served as a Baxter director since 2012 and currently serves as the chair of our Nominating, Corporat","filed_date":"2023-03-23","accession":"0001193125-23-077304","full_text":"https://origin.rootz.global/static/filing/0001193125-23-077304.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":16,"context":"s, rationalizing our manufacturing and distribution facilities, reducing our general and administrative infrastructure, re-aligning certain R&D activities and canceling certain R&D programs. In 2022, restructuring charges include actions taken in connection with our integration of Hillrom, which we acquired in December 2021. Our results in 2022 and 2021 included business optimization charges of $225 million and $114 m","filed_date":"2023-02-09","accession":"0001628280-23-002864","full_text":"https://origin.rootz.global/static/filing/0001628280-23-002864.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":100,"match_count":1,"context":", necessitating significant multi-year capital expenditures in order to meet that demand. However, the impact of such changes and related expenses are difficult to estimate in advance. In addition, a substantial portion of our revenues is dependent on federal healthcare program reimbursement, and any disruptions in federal government operations, including a federal government shutdown or failure of the U.S. government to enact ann","filed_date":"2023-02-09","accession":"0001628280-23-002864","full_text":"https://origin.rootz.global/static/filing/0001628280-23-002864.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":50,"context":"tion under the captions Risks Related to Baxters BusinessWe are subject to risks associated with doing business globally and Changes in foreign currency exchange rates and interest rates could have a material adverse effect on our operating results and liquidity in Item1A of this Annual Report on Form 10-K. For financial information about our foreign and domestic revenues and segment information, see Notes 10 and 17, re","filed_date":"2023-02-09","accession":"0001628280-23-002864","full_text":"https://origin.rootz.global/static/filing/0001628280-23-002864.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":14,"context":"mizing the manufacturing footprint, R&D operations and supply chain network, employing disciplined cost management, and centralizing and streamlining certain support functions. In the current period, restructuring charges include actions taken in connection with our integration of Hillrom. From the commencement of our business optimization activities in the second half of 2015 through September30, 2022, we have incurr","filed_date":"2022-10-27","accession":"0001628280-22-027149","full_text":"https://origin.rootz.global/static/filing/0001628280-22-027149.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":14,"context":"mizing the manufacturing footprint, R&D operations and supply chain network, employing disciplined cost management, and centralizing and streamlining certain support functions. In the current period, restructuring charges include actions taken in connection with our integration of Hillrom. From the commencement of our business optimization activities in the second half of 2015 through June30, 2022, we have incurred cu","filed_date":"2022-07-28","accession":"0001628280-22-019640","full_text":"https://origin.rootz.global/static/filing/0001628280-22-019640.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"ernational business experience in hospital products and pharmaceuticals Global perspective resulting from a focus on emerging markets (including China) |  |  |  |  |  |  |  |  | | |  |  |  Peter S. Hellman President and Chief Financial and Administrative Officer, Nordson Corporation (retired) |  |  72 |  |  2005 |  |  Y |  |  Extensive financial and capital markets experience Significant experience l","filed_date":"2022-03-21","accession":"0001193125-22-080632","full_text":"https://origin.rootz.global/static/filing/0001193125-22-080632.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":23,"context":"tant, the Compensation Committee reviewed Baxters material compensation policies and practices and concluded that these policies and practices do not create risks that are reasonably likely to have a material adverse effect on the company. The key features of the executive compensation program that support this conclusion include:  |  |  |  |  appropriate pay philosophy, peer group and market positioning; | | |  |  |  |","filed_date":"2022-03-21","accession":"0001193125-22-080632","full_text":"https://origin.rootz.global/static/filing/0001193125-22-080632.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":33,"context":"y committed to personally overseeing the successful integration of our organizations a process that is already well underway.  Also providing critical leadership is Giuseppe Accogli, who was recently named our executive vice president and chief operating officer (COO). Giuseppe is a 14-year Baxter veteran, experienced across an array of senior management positions. As COO, his top priorities include advancing a rapid, smooth integ","filed_date":"2022-03-21","accession":"0001193125-22-080632","full_text":"https://origin.rootz.global/static/filing/0001193125-22-080632.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":100,"match_count":1,"context":", necessitating significant multi-year capital expenditures in order to meet that demand. However, the impact of such changes and related expenses are difficult to estimate in advance. In addition, a substantial portion of our revenues is dependent on federal healthcare program reimbursement, and any disruptions in federal government operations, including a federal government shutdown or failure of the U.S. government to enact ann","filed_date":"2022-02-23","accession":"0001628280-22-003432","full_text":"https://origin.rootz.global/static/filing/0001628280-22-003432.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":47,"context":"tion under the captions Risks Related to Baxters BusinessWe are subject to risks associated with doing business globally and Changes in foreign currency exchange rates and interest rates could have a material adverse effect on our operating results and liquidity in Item1A of this Annual Report on Form 10-K. For financial information about our foreign and domestic revenues and segment information, see Note 17 in Item8 of","filed_date":"2022-02-23","accession":"0001628280-22-003432","full_text":"https://origin.rootz.global/static/filing/0001628280-22-003432.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":13,"context":"ntained in Section 7.01 and in Section 11 of the Amended and Restated Guaranty are true and correct in all material respects (or, if any such representation or warranty is qualified by materiality or material adverse effect, it is true and correct in all respects) on and as of the First Amendment Effective Date as though made on and as of First Amendment Effective Date (except to the extent that such representations and","filed_date":"2021-10-04","accession":"0001193125-21-290255","full_text":"https://origin.rootz.global/static/filing/0001193125-21-290255.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":42,"context":"|  |  |  Y |  |  |  Extensive international business experience in hospital products and pharmaceuticals  Global perspective |  |  |  |  |  |  2 |  |  | | |  |  |  John D. Forsyth Chairman and CEO, Wellmark Blue Cross Blue Shield (retired) |  |  |  73 |  |  |  |  2003 |  |  |  |  Y |  |  |  Significant experience in the healthcare industry, including with leading payors Understanding of large, comple","filed_date":"2021-03-22","accession":"0001193125-21-089604","full_text":"https://origin.rootz.global/static/filing/0001193125-21-089604.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":23,"context":"ockholders and continuing to enhance its corporate citizenship and ESG programs. Notwithstanding these significant accomplishments and the companys strong performance for the year but in light of the substantial negative impact of the ongoing pandemic on the companys employees, patients, customers, stockholders and other stakeholders generally, Mr. Almeida recommended to the full Board that his 2020 annual incentive payout","filed_date":"2021-03-22","accession":"0001193125-21-089604","full_text":"https://origin.rootz.global/static/filing/0001193125-21-089604.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":40,"context":"tors (the Board) are always evolving to ensure dynamic, effective corporate oversight, which includes our continued outreach and engagement with Baxter investors. In 2020, Albert Stroucken (our newly appointed Lead Independent Director and former Audit Committee Chair) and Thomas Stallkamp (our former Lead Independent Director) spoke with investors representing over 40% of our outstanding shares as of December 31, 2020. These discu","filed_date":"2021-03-22","accession":"0001193125-21-089604","full_text":"https://origin.rootz.global/static/filing/0001193125-21-089604.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":37,"context":"tion under the captions Risks Related to Baxters BusinessWe are subject to risks associated with doing business globally and Changes in foreign currency exchange rates and interest rates could have a material adverse effect on our operating results and liquidity in Item1A of this Annual Report on Form 10-K. For financial information about our foreign and domestic revenues and geographic segment information, see Note 16","filed_date":"2021-02-11","accession":"0001628280-21-001867","full_text":"https://origin.rootz.global/static/filing/0001628280-21-001867.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":13,"context":"esolution thereof in any reporting period could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur","filed_date":"2020-10-29","accession":"0001628280-20-015042","full_text":"https://origin.rootz.global/static/filing/0001628280-20-015042.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BAX","company":"BAXTER INTERNATIONAL INC","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":13,"context":"esolution thereof in any reporting period could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur","filed_date":"2020-07-30","accession":"0001628280-20-010911","full_text":"https://origin.rootz.global/static/filing/0001628280-20-010911.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"14f1e211df0d334a885b2558e79f73da1ce1d0283f2824d24489a505103c685b","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"c4a719214d9591ebe1b4bc8c8d9530f81ba5257cf77339c1a97f2431fae2d116","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":134,"hourly_limit":500,"remaining":366,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}